Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations

References

• Maggi L, Machiste EO, Torre ML, Conte U. (1999). Formulation of biphasic release tablets containing slightly soluble drugs. Eur J Pharm Biopharm, 48:37–42.
   PubMed Web of Science ®Google Scholar
• Lopes CM, Sousa Lobo JM, Pinto JF, Costa PC. (2007). Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen. AAPS PharmSciTech, 8(3):E76.
   PubMedGoogle Scholar
• Homdrum EM, Likar R, Nell G. (2006). Xefo® rapid: A novel effective tool for pain treatment. Eur Surg, 38:342–52.
   Google Scholar
• Kidd B, Frenzel W. (1996). A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol, 23:1605–11.
   PubMed Web of Science ®Google Scholar
• Rainer F, Klein G, Mayrhofer F. (1996). A prospective, multicentre, open-label, uncontrolled Phase II study of the local tolerability, safety and efficacy of intramuscular chlortenoxicam in patients with acute low back pain. Eur J Clin Res, 8:1–13.
   Google Scholar
• Staunstrup H, Ovesen J, Larsen UT, Elbaek K, Larsen U, Kroner K. (1999). Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. J Clin Pharmacol, 39:834–41.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. (2005). Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol, 59:14–7.
   PubMed Web of Science ®Google Scholar
• Aabakken L, Osnes M, Frenzel W. (1996). Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment Pharmacol Ther, 10:151–6.
   PubMed Web of Science ®Google Scholar
• Kehlet H, Dahl JB. (1992). Are perioperative nonsteroidal anti-inflammatory drugs ulcerogenic in the short term? Drugs, 44(Suppl. 5):38–41.
   PubMedGoogle Scholar
• Skjodt NM, Davies NM. (1998). Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet, 34:421–8.
   PubMed Web of Science ®Google Scholar
• Balfour JA, Fitton A, Barradell LB. (1996). Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs, 51:639–57.
   PubMed Web of Science ®Google Scholar
• El-Badry M, Fathy M. (2006). Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30. Drug Dev Ind Pharm, 32:141–50.
   PubMed Web of Science ®Google Scholar
• Pan RN, Chen JH, Chen RR. (2000). Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems. Drug Dev Ind Pharm, 26:989–94.
   PubMed Web of Science ®Google Scholar
• Shah J, Vasanti S, Anroop B, Vyas H. (2009). Enhancement of dissolution rate of Valdecoxib by solid dispersions technique with PVP K 30 & PEG 4000: Preparation and in vitro evaluation. J Incl Phenom Macrocyclic Chem, 63:69–75.
   Web of Science ®Google Scholar
• Thybo P, Pedersen BL, Hovgaard L, Holm R, Mullertz A. (2008). Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30. Pharm Dev Tech, 13:375–86.
   PubMed Web of Science ®Google Scholar
• Patel RP, Patel MM. (2007). Physicochemical characterization and dissolution study of solid dispersions of lovastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30. Pharm Dev Tech, 12:21–33.
   PubMed Web of Science ®Google Scholar
• Damian F, Blaton N, Kinget R, Van den Mooter G. (2002). Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire® 44/14 and PVP K30. Int J Pharm, 24:87–98.
   Google Scholar
• Thybo P, Kristensen J, Hovgaard L. (2007). Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions. Pharm Dev Tech, 12:43–53.
   PubMed Web of Science ®Google Scholar
• Özyazici M, Gökçe EH, Ertan G. (2006). Release and diffusional modeling of metronidazole lipid matrices. Eur J Pharm Biopharm, 63:331–9.
   PubMed Web of Science ®Google Scholar
• Gu X, Fediuk DJ, Simons FE, Simons KJ. (2004). Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrine. Drug Dev Ind Pharm, 30:1009–17.
   PubMed Web of Science ®Google Scholar
• Barthelemy P, Laforêt JP, Farah N, Joachim J. (1999). Compritol® 888 ATO: An innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm, 47:87–90.
   PubMed Web of Science ®Google Scholar
• Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol, 27:48–9.
   PubMed Web of Science ®Google Scholar
• Liew CV, Chan LW, Ching AL, Heng PW. (2006). Evaluation of sodium alginate as drug release modifier in matrix tablets. Int J Pharm, 309:25–37.
   PubMed Web of Science ®Google Scholar
• Lin SY, Lin KH, Li MJ. (2004). Formulation design of double-layer in the outer shell of dry-coated tablet to modulate lag time and time-controlled dissolution function: Studies on micronized ethylcellulose for dosage form design (VII). AAPS J, 6(3):e17.
   PubMedGoogle Scholar
• British Pharmacopoeia. (2007). British Pharmacopoeia Commission. London: HMSO (Electronic version).
   Google Scholar
• Lopes CM, Sousa Lobo JM, Pinto JF, Costa P. (2006). Compressed mini-tablets as a biphasic delivery system. Int J Pharm, 323:93–1000.
   PubMed Web of Science ®Google Scholar
• O’Neill MJ, Smith A, Heckelman PE, Budavari S, eds. (2001). The Merck Index, 13th ed. Whitehouse Station, NJ: Merck & Co. Inc.
   Google Scholar
• Abdelkader H, Abdallah OY, Salem HS. (2007). Comparison of the effect of tromethamine and polyvinylpyrrolidone on dissolution properties and analgesic effect of nimesulide. AAPS PharmSciTech, 8(3):E65.
   PubMedGoogle Scholar
• Modi A, Tayade P. (2006). Enhancement of dissolution profile by solid dispersion (kneading) technique. AAPS PharmSciTech, 7(3):68.
   PubMed Web of Science ®Google Scholar
• Kalaiselvan R, Mohanta GP, Manna PK, Manavalan R. (2006). Studies on mechanism of enhanced dissolution of albendazole solid dispersions with crystalline carriers. Indian J Pharm Sci, 68:599–607.
   Google Scholar
• Zheng X, Yang R, Tang X, Zheng L. (2007). Part I: Characterization of solid dispersions of nimodipine prepared by hot-melt extrusion. Drug Dev Ind Pharm, 33:791–802.
   PubMed Web of Science ®Google Scholar
• Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. (2007). Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm, 66: 334–47.
   PubMed Web of Science ®Google Scholar
• Nokhodchi A, Talari R, Valizadeh H, Jalali MB. (2007). An investigation on the solid dispersions of chlordiazepoxide. Int J Biomed Sci, 3:211–7.
   PubMedGoogle Scholar
• Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. (1999). Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm, 181:143–51.
   PubMed Web of Science ®Google Scholar
• Ambike AA, Mahadik KR, Paradkar A. (2004). Stability study of amorphous valdecoxib. Int J Pharm, 282:151–62.
   PubMed Web of Science ®Google Scholar
• Prabhu S, Brocks DR, Betageri GV. (2001). Enhancement of dissolution of ethopropazine using solid dispersions prepared with phospholipids and/or polyethylene glycol. Drug Dev Ind Pharm, 27:413–8.
   PubMed Web of Science ®Google Scholar
• Varma MM, Pandi JK. (2005). Dissolution, solubility, XRD, and DSC studies on flurbiprofen-nicotinamide solid dispersions. Drug Dev Ind Pharm, 31:417–23.
   PubMed Web of Science ®Google Scholar
• Sekikawa H, Nakano M, Arita T. (1978). Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem Pharm Bull, 26:118–26.
   Web of Science ®Google Scholar
• Ribeiro L, Ferreira DC, Veiga FJ. (2005). In vitro controlled release of vinpocetine–cyclodextrin–tartaric acid multicomponent complexes from HPMC swellable tablets. J Control Release, 103:325–39.
   PubMed Web of Science ®Google Scholar
• Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. (1984). A comparative study of the gastrointestinal transit of a pellet and tablet formulation. Int J Pharm, 21:167–77.
   Web of Science ®Google Scholar
• Yonezawa Y, Ishida S, Sunanda H. (2001). Release from or through a wax matrix system. I. Basic release properties of the wax matrix system. Chem Pharm Bull, 49:1448–51.
   PubMed Web of Science ®Google Scholar
• Li FQ, Hu JH, Deng JX, Su H, Xu S, Liu JY. (2006). In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets. Int J Pharm, 324:152–7.
   PubMed Web of Science ®Google Scholar
• El-Malah Y, Nazzal S, Khanfar NM. (2006). D-optimal mixture design: Optimization of ternary matrix blends for controlled zero-order drug release from oral dosage forms. Drug Dev Ind Pharm, 32:1207–18.
   PubMed Web of Science ®Google Scholar
• Huang YB, Tsai YH, Yang WC, Chang JS, Wu PC, Takayama K. (2004). Once-daily propranolol extended-release tablet dosage form: Formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm, 58:607–14.
   PubMed Web of Science ®Google Scholar
• Kranz H, Wagner T. (2006). Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations. Eur J Pharm Biopharm, 62:70–6.
   PubMed Web of Science ®Google Scholar
• Cohen JL, Hubert BB, Rhodes CT. (1990). The development of USP dissolution and drug release standards. Pharm Res, 7: 983–7.
   PubMed Web of Science ®Google Scholar